Literature DB >> 2463874

Correlation of prostate-specific acid phosphatase and prostate-specific antigen immunocytochemistry with survival in prostate carcinoma.

M E Hammond1, W T Sause, K L Martz, M V Pilepich, S O Asbell, P Rubin, R P Myers, G M Farrow.   

Abstract

Prostate-specific acid phosphatase, a secretory product of prostatic cells, may be a secondary product of the interaction of hormones with their receptor proteins. In this study we have examined two independent patient populations to see whether the intensity or extent of prostate-specific acid phosphatase and/or prostate-specific antigen staining correlated with survival and hormonal manipulation. One population of 24 patients was selected from patients undergoing surgical resection for adenocarcinoma Stage B or C at the Mayo Clinic. The second population of 123 patients was obtained from Radiation Therapy Oncology Group Protocols 75-06 and 77-06. Tissue from both populations was analyzed. In both populations, the intensity of prostate-specific acid phosphatase staining correlated with survival in a statistically significant manner. Staining with prostate-specific antigen was present in greater than 90% of specimens; data was therefore not analyzed. In those patients who subsequently relapsed and were subjected to hormonal manipulation, there appeared to be a higher likelihood of response to hormones with intense prostate-specific acid phosphatase staining.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2463874     DOI: 10.1002/1097-0142(19890201)63:3<461::aid-cncr2820630312>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Use of tumour marker immunoreactivity to identify primary site of metastatic cancer.

Authors:  A R Gamble; J A Bell; J E Ronan; D Pearson; I O Ellis
Journal:  BMJ       Date:  1993-01-30

2.  Hormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre- and post-treatment specimens.

Authors:  A Berner; J M Nesland; H Waehre; J Silde; S D Fosså
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

3.  Prostatic carcinoma: a multivariate analysis of prognostic factors.

Authors:  A Berner; S Harvei; S Tretli; S D Fosså; J M Nesland
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.